COVID-19: DCGI grants emergency use authorization to Covovax for children over the age of 12

new Delhi: The Drugs Controller General of India (DCGI) has granted Emergency Use Authorization (EUA) to the Serum Institute of India (SII)’s COVID-19 vaccine Covovax for adults and children above 12 years of age.

“Novavax has demonstrated over 90 percent efficacy in global trials. Serum Institute of India brand Kovovax has completed bridging studies in India and granted emergency use authorization by DCGI for adults and children above 12 years of age. Younger age group to follow soon,” tweeted SII CEO Adar Poonawalla.

Recently, a subject expert committee recommended emergency use authorization to Kovovax for the age group of 12 to 17 years. Earlier, DCGI had on December 28 last year approved Kovovax for restricted use in emergency situations for adults.

Following emergency use authorization from DCGI, Covovax will become the fourth vaccine that can be administered to the age group of 12-17 years. This vaccine has not yet been included in the country’s vaccination program.

Covovax also approved emergency use list by WHO. It is manufactured by transfer of technology from Novavax and is approved by the European Medicines Agency for conditional marketing. (ANI)

First published:March 9, 2022, 6:35 pm

Leave a Reply